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After selection for resistance to a single cytotoxic drug, tumour
cells may become resistant against a whole range of drugs with
different chemical structures and cellular targets, a phenomenon
called multidrug resistance (MDR) (Higgins, 1992). Membrane
proteins belonging to the ATP-binding cassette (ABC) family of
transport proteins play a central role in resistance by actively
decreasing the intracellular drug concentration. In humans, two
members of the ABC-transporter family have been identified that
can render tumour cells MDR: MDR1 P-glycoprotein (Pgp)
(Gottesman et al, 1995), and the multidrug resistance protein
(MRP1) (Cole and Deeley, 1998).
Overexpression of MRP1 is associated with an increased trans-
port rate of a range of substrates that are conjugated to glutathione
(GSH), glucuronide, or sulfate (Leier et al, 1994; Müller et al,
1994; Jedlitschky et al, 1997). Transporters with these characteris-
tics are known as glutathione conjugate (GS-X) pumps (Ishikawa,
1992), or multispecific organic anion transporters (Oude Elferink
et al, 1995). Besides organic anions MRP1 can also transport
neutral and basic cytotoxic drugs not known to be conjugated to
GSH or other negatively charged compounds (Cole et al, 1994;
Zaman et al, 1994). Nevertheless, MRP1 requires the presence
of intracellular glutathione for the transport of these drugs
(Versantvoort et al, 1995; Zaman et al, 1995). The data available
are most consistent with a model in which MRP1 co-transports
cytotoxic drugs with GSH (Rappa et al, 1997; Loe et al, 1998).
Another ABC-transporter that shows homology to MRP1 is the
canalicular multispecific organic anion transporter (cMOAT or
MRP2) (Büchler et al, 1996; Paulusma et al, 1996; 1997; Ito et al,
1997). It is plausible that MRP2 could play a role in drug resis-
tance, just as MRP1 does. Studies with mutant rats (TR–/GY or
EHBR) that lack the MRP2 protein in the hepatocanalicular
membrane and transfection studies with MRP2 cDNA showed that
the substrate specificity of MRP2 is very similar to that of MRP1
(Jedlitschky et al, 1997), and suggested that MRP2 is able to trans-
port several anticancer drugs (Chu et al, 1997; Masuda et al, 1997;
Cui et al, 1999).
We previously made a set of Madin–Darby Canine Kidney
(MDCKII)-derived cell lines stably expressing human MRP1,
MRP2 or MDR1 cDNA. In these polarized cell lines MRP1 routes
to the lateral plasma membrane, whereas MRP2 and MDR1 Pgp
localize to the apical plasma membrane. MDCKII-MRP1 cells
transport several glutathione S-conjugates to the basal side of a
monolayer, and MDCKII-MRP2 cells to the apical side. Moreover,
in these transfected cells MRP1 can transport the anthracycline
daunorubicin and MRP2 the vinca alkaloid vinblastine (Bakos et
al, 1998; Evers et al, 1998). Paulusma et al (1999) recently showed
that MDCKII-MRP1 and MDCKII-MRP2 cells also export
reduced glutathione in the absence of drugs, resulting in a lowered
intracellular glutathione concentration in these cells.
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Summary The multidrug resistance proteins MRP1 and MRP2 are members of the same subfamily of ATP-binding cassette transporters.
Besides organic molecules conjugated to negatively charged ligands, these proteins also transport cytotoxic drugs for which no negatively
charged conjugates are known to exist. In polarized MDCKII cells, MRP1 routes to the lateral plasma membrane, and MRP2 to the apical
plasma membrane. In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH)
into the medium. We demonstrate that glutathione transport in MDCKII-MRP1 cells is inhibited by the inhibitors of organic anion transporters
sulfinpyrazone, indomethacin, probenecid and benzbromarone. In MDCKII-MRP2 cells, GSH export is stimulated by low concentrations of
sulfinpyrazone or indomethacin, whereas export is inhibited down to control levels at high concentrations. We find that unmodified
sulfinpyrazone is a substrate for MRP2, also at concentrations where GSH export is inhibited. We also show that GSH export in MDCKII-
MRP2 cells increases in the presence of vinblastine, and that the stochiometry between drug and GSH exported is between two and three.
Our data indicate that transport of sulfinpyrazone and vinblastine is associated with GSH export. However, at high sulfinpyrazone
concentrations this compound is transported without GSH. Models of MRP action are discussed that could explain these results. © 2000
Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1262, available online at http://www.idealibrary.com on In this study, we present a more detailed investigation of GSH
export by MDCKII-MRP1 and MDCKII-MRP2 cells.
MATERIALS AND METHODS
Materials
[3H]Vinblastine (15 Ci mmol–1) was obtained from Amersham
International (Little Chalfont, UK). Acivicin, sulfinpyrazone,
benzbromarone, indomethacin, and probenecid were obtained
from Sigma Chemical Co. (St. Louis, MO, USA). GSH, NADPH,
and glutathione reductase were from Boehringer (Mannheim,
Germany).
Cell lines
Polarized Madin–Darby Canine Kidney (MDCKII) cells stably
expressing human cMOAT(MRP2), MRP1, or MDR1 cDNA have
been described before (Bakos et al, 1998; Evers et al, 1998).
Previously, we described several MDCKII-cMOAT clones (Evers
et al, 1998). In this study MDCKII-cMOAT17 cells were used, and
in this paper we will refer to these cells as MDCKII-MRP2. Cells
were cultured in DMEM with 10% foetal calf serum.
GSH export assays
Cells were grown on microporous polycarbonate filters (3 mm
pore size, 24.5 mm diameter, Transwell™ 3414; Costar Corp,
Cambridge, MA, USA) as described before (Evers et al, 1998).
Cells were cultured for 3 days. Medium was replaced daily and 2 h
before starting the experiment. GSH-transport experiments were
performed in Hanks Balanced Salt Solution (HBSS plus CaCl2
(1.3 mM); 1 ml per compartment) in the presence of acivicin
(0.5 mM) at 37°C and 5% CO2. Samples were taken at the time-
points indicated and total glutathione was determined according to
the recycling method of Tietze (1969). Previous experiments have
shown that less than 2% of total glutathione was in the oxidized
(GSSG) from (Paulusma et al, 1999). Intracellular GSH was deter-
mined by dissolving the cells in 10% perchloric acid. Precipitated
proteins were removed by centrifugation, and samples were
neutralized by adding a solution containing MOPS (0.5 M) and
KOH (5 M). Glutathione was determined as described above.
Transport assays
[3H]Vinblastine transport assays were carried out essentially as
described (Evers et al, 1998), with the modification that HBSS
medium was used instead of DMEM. Cells were seeded on poly-
carbonate filters (see above). The experiment was started by
adding 2 ml of HBSS containing acivicin (0.5 mM), PSC833
(0.1 mM), and the indicated amount of drug to either the apical or
basal compartment. Cells were incubated at 37°C in 5% CO2,
and 50 ml aliquots were taken at the time-points indicated.
Radioactivity was measured as the fraction of total radioactivity
added at the beginning of the experiment. Sulfinpyrazone trans-
port was determined as for vinblastine. Samples were split into
two halves: one half was used for measuring the glutathione
concentration, the other for measuring sulfinpyrazone.
Sulfinpyrazone concentrations were measured by HPLC. After a
2–20-fold dilution with water, samples (20 ml) were injected
on a Symmetry C18 column (100 ´ 4.6 mm; 3.5 mm, Waters
chromatography (Milford, MA, USA) at ambient temperature. The
eluent comprised acetonitrile (55% v/v), water (44.9% v/v), and
trifluoroacetic acid (0.1% v/v). The eluent flow was 1 ml min–1
and UV-absorption at a wavelength of 240 nm was used as the
detection method. The retention time of sulfinpyrazone was
2.5 min under these conditions. Dilutions of sulfinpyrazone in
water were used as calibration standards.
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Table 1 Inhibition of GSH flux by MDCKII-derived clones by benzbromarone, probenecid, or indomethacin
Total GSH (nmoles per monolayer)
MDCKII MDCKII-MRP1 MDCKII-MRP2
In medium In medium In medium
Apicala Basala Intracellulara Apicala Basala Intracellulara Apicala Basala Intracellulara
Control 0.6 ± 0.1 1.1 ± 0.0 31.8 ± 2.9 0.7 ± 0.1 9.3 ± 1.5 3.8 ± 1.3 3.2 ± 0.2 0.8 ± 0.1 25.7 ± 3
Probenecid (1 mM) 0.2 ± 0.0 0.5 ± 0.0 37.4 ± 0.2 0.5 ± 0.0 9.1 ± 0.8 6.7 ± 0.5 1.9 ± 0.0 0.4 ± 0.0 25.4 ± 1.0
(5 mM) 0.0 ± 0.0 0.1 ± 0.0 41.3 ± 0.2 0.1 ± 0.0 0.9 ± 0.0 13.3 ± 1.4 1.3 ± 0.0 0.1 ± 0.0 30.4 ± 1.0
Benzbromarone (5 mM) 0.6 ± 0.0 0.7 ± 0.0 31.4 ± 1.5 0.4 ± 0.0 4.5 ± 0.0 5.6 ± 0.0 2.7 ± 0.3 0.5 ± 0.2 20.2 ± 0.4
(25 mM) 0.5 ± 0.1 0.6 ± 0.0 32.3 ± 3.3 0.1 ± 0.1 0.6 ± 0.0 10.5 ± 0.7 0.7 ± 0.0 0.1 ± 0.1 23.0 ± 1.5
Indomethacin   (25 mM) 4.8 ± 0.1 1.1 ± 0.1 28.3 ± 0.9 0.6 ± 0.1 11.6 ± 0.6 0.8 ± 0.2 9.6 ± 0.2 0.7 ± 0.0 15.8 ± 0.3
(50 mM) 5.5 ± 0.2 1.0 ± 0.3 28.8 ± 2.2 0.5 ± 0.1 10.7 ± 1.0 1.2 ± 0.1 11.4 ± 0.0 0.7 ± 0.0 15.0 ± 1.2
(100 mM) 4.2 ± 0.0 0.6 ± 0.1 29.3 ± 3.6 0.4 ± 0.1 9.6 ± 1.2 2.0 ± 0.4 10.5 ± 0.2 0.6 ± 0.0 16.4 ± 0.0
(200 mM) 2.5 ± 0.3 0.6 ± 0.1 37.4 ± 0.2 0.2 ± 0.0 7.0 ± 0.3 4.3 ± 0.3 7.7 ± 0.1 0.5 ± 0.0 18.1 ± 1.4
(400 mM) 1.5 ± 0.2 0.4 ± 0.0 36.8 ± 0.7 0.3 ± 0.0 4.2 ± 0.2 8.3 ± 1.3 4.5 ± 0.1 0.3 ± 0.0 21.8 ± 0.2
aNumbers in the table represent amounts of GSH (in nmoles per monolayer) fluxed into the apical or basal medium at t = 2 h, respectively. ‘Intracellular’
represents amounts of GSH measured in the cell lysates at t = 2 h. Cells growing in a monolayer were incubated in the presence of the inhibitors indicated.
Inhibitors were added to both the apical and basal compartment. At t = 2 h samples were taken from both compartments and the GSH concentration was
determined. To determine the total amount of intracellular glutathione at t = 2 h, cells were lysed and the amount of glutathione in the cell lysates was
determined. Values are means of one typical experiment performed in duplicate ± the variation between the two measurements.In experiments where the effect of cytotoxic drugs or inhibitors
on GSH-transport was determined, compounds were added to both
the apical and basal compartment at t = 0, unless indicated
otherwise. Samples (50 ml) were taken at the time-points indicated.
Calculations
Net flux at a particular substrate concentration was calculated by
determining the net difference between the flux from basolateral to
apical (ba), and vice versa (ab), in a transport experiment. The
pump-mediated flux is controlled by the internal free substrate
concentration. The latter is the result of both active and passive
drug fluxes. As we observed a constant flux over time in our
experiments, we concluded that the cellular loading time was
relatively short. The intracellular concentration was therefore
considered to be constant at the time-scale of the measurements.
The reasoning below shows that the net flux equals the pump-
mediated flux for the simple case when: i) the pump-mediated flux
follows Michaelis–Menten kinetics; ii) the substrate concentration
is far below the Km; and iii) the contribution of other transport
proteins with very different transport characteristics is negligible.
MRP and drug/glutathione transport 377
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Figure 1 Flux of GSH from MDCKII-derived clones in the presence of sulfinpyrazone. At t = 0 the indicated concentrations of sulfinpyrazone were applied to
both the apical and basal side (in 1 ml HBSS per compartment) and the amount of glutathione appearing in the apical and basal compartment was determined.
Samples were taken at t = 30, 60, and 120 min. Panels A, B and C: MDCKII, MDCKII-MRP1 and MDCKII-MRP2 cells were analysed, respectively. Experiments
were performed in duplicate. Variations were within the size of the symbolsAs:
total flux = flux through the cells + flux between the cells
and:
net flux = flux through the cellsba – flux through the cellsab
The term for flux between the cells cancels out in this subtraction
as Ca = Cb, in both compartments, where Ca = concentration in
apical compartment and Cb = concentration in basolateral
compartment.
For the case of MRP2-mediated transport into the apical
compartment, considering no backflux from the apical compart-
ment and at quasi steady-state (at constant Ci):
net flux = Ci,ba ka + Ci,ba Vmax/Km – Ci,ab kb (eq. 1)
In which: Ci,ba = intracellular free substrate concentration for flux
from basal to apical transport (mol L–1); Ci,ab = intracellular free
substrate concentration for flux from apical to basal transport
(mol l–1); ka = permeation coefficient of apical plasma membrane
(l min–1 well–1); kb = permeation coefficient of basolateral plasma
membrane (l min–1 well–1); Vmax = maximum pumping rate (mol
min–1 well–1); Km = Michaelis constant for pumping (mol l–1).
Expressions for Ci,ba and Ci,ab can be found from the mass balances:
Cbkb – Ci,bakb = Ci,baka + Ci,ba Vmax/Km
and:
Caka – Ci,ab Vmax/Km – Ci,ab ka = Ci,ab kb
Substitution of Ci,ab and Ci,ba into eq. 1 (at Ca = Cb) leads to:
net flux = Ci,ba Vmax/Km, which equals pump-mediated fluxba.
RESULTS
Inhibition of GSH-transport
To assess whether classical inhibitors of organic anion transporters
were able to inhibit the export of GSH in MDCKII-MRP1 and
MDCKII-MRP2 cells, we measured GSH export in the presence of
various concentrations of sulfinpyrazone, indomethacin,
probenecid, or benzbromarone. Cells were grown in a monolayer
on a porous membrane, enabling the measurement of polarized
transport to both the apical and basolateral side of the cell mono-
layer. GSH export in the presence of sulfinpyrazone is shown in
Figure 1; data obtained with the other compounds are summarized
in Table 1. At relatively high concentrations a clear inhibition of
the GSH export to the basolateral side of the cell monolayer was
observed with all compounds in the MDCKII-MRP1 cells. Apical
export in MDCKII-MRP2 cells was completely inhibited by
benzbromarone, and partially by probenecid, but not by sulfin-
pyrazone or indomethacin. Unexpectedly, sulfinpyrazone and
indomethacin strongly stimulated apical GSH export in MDCKII-
MRP2 cells at relatively low concentrations (Figure 1C, Figure
2A, and Table 1). At higher concentrations, export of GSH started
decreasing, but export could not be inhibited to the level observed
in wild-type cells. Low concentrations of sulfinpyrazone also
weakly stimulated the apical GSH flux by MDCKII wild-type
cells (Figure 1A). This is probably caused by the presence of
canine MRP2 in these cells (see Evers et al, 1998). Basolateral
GSH export in the MDCKII-MRP1 cells was slightly stimulated
by sulfinpyrazone and indomethacin. After incubation in the pres-
ence of inhibitors the intracellular glutathione levels roughly
correlated in an inverse manner with the amounts of GSH that
were exported (see Table 1 and Figure 2B). The inhibitory effect of
high concentrations of sulfinpyrazone on the export of GSH was
not simply due to a toxic effect as MDR1-mediated vinblastine
transport by MDCKII-MDR1 cells was not affected (data not
shown).
Sulfinpyrazone transport by MDCKII derived clones
A possible explanation for the stimulatory effect of sulfinpyrazone
on GSH export is that both compounds are co-transported with
positive cooperativity. To test this hypothesis, we studied vectorial
transport of sulfinpyrazone in MDCKII and MDCKII-MRP2
cells. Various concentrations of sulfinpyrazone were added to
either the apical or basolateral side of the cell monolayer, and the
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Figure 2 Dose–response for sulfinpyrazone induced GSH flux and intracellular GSH levels. (A) Dose–response curve for sulfinpyrazone added to medium,
and GSH exported into the basal (for MRP1; n n) or apical (for MRP2; l l) medium, respectively. The GSH levels measured at t = 2 h were plotted (data derived
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.accumulation of sulfinpyrazone appearing in the opposite
compartment was followed by a quantitative HPLC method
(Figure 3). The total amount of sulfinpyrazone in the transport
wells, as measured in the samples from both compartments, did
not decrease in the course of the experiment, indicating that sulfin-
pyrazone was not metabolized by these cells (data not shown). The
apical flux was higher than the basolateral flux in wild-type cells,
suggesting that the MDCKII cells contain an endogenous apical
transport mechanism for sulfinpyrazone. At all concentrations
tested the amount of sulfinpyrazone translocated to the apical
compartment was substantially higher in MDCKII-MRP2 than in
wild-type cells, resulting in a clearly higher net flux of sulfinpyra-
zone in MDCKII-MRP2 cells (Table 2). Between 0.2 mM and
0.8 mM sulfinpyrazone net flux increased 3.3-fold, whereas
between 0.8 mM and 3.2 mM this increase was only 1.8-fold,
indicating that at sulfinpyrazone concentrations above 0.8 mM,
transport became saturated. We conclude from these experiments
that MRP2 causes vectorial transport of sulfinpyrazone.
To assess the correlation between the amounts of sulfinpyrazone
and GSH transported by the MDCKII and MDCKII-MRP2 cells,
GSH concentrations were measured in the same samples that were
used for the sulfinpyrazone determinations. A complication of this
experiment was that the amount of sulfinpyrazone required to
inhibit GSH export was higher if sulfinpyrazone was added to the
apical than to the basal compartment (Table 2, and see Wielinga et
al, 1999). For further calculations the amounts of GSH exported to
the apical compartment after adding sulfinpyrazone to the basal
compartment were used. After 2 h the ratio between the amount of
sulfinpyrazone and GSH transported in the MDCKII-MRP2 cells
increased from 3.1 at 0.2 mM sulfinpyrazone to 91 at 3.2 mM
(Table 2). These data suggest that at low sulfinpyrazone concentra-
tions, where transport is most efficient, sulfinpyrazone transport is
associated with GSH export, but that at high sulfinpyrazone
concentrations this compound is transported without GSH.
We note in passing that the basal GSH excretion of MDCKII
parental cells and MRP2 transfectants varies somewhat depending
on the time cells were kept in culture (see e.g. Table 2). These
variations did not affect the drug-induced GSH stimulation.
Vinblastine-induced glutathione transport in MDCKII-
MRP2 cells
We have previously shown that vinblastine is transported to
the apical side of MDCKII-MRP2 cells (Evers et al, 1998). As
MDCKII cells contain a relatively high concentration of MDR1
Pgp in the apical membrane (Horio et al, 1989), these experiments
were performed in the presence of a low concentration of the Pgp
inhibitor PSC833 (0.1 mM). This concentration of PSC833 does
not significantly affect MRP2, whereas the endogenous MDR1
Pgp activity is efficiently blocked. We investigated whether
vinblastine transport had an effect on the amount of GSH exported
by MDCKII-MRP2 and wild-type cells. Figure 4 shows that GSH
export to the apical side of a MDCKII-MRP2 cell monolayer
strongly increased with increasing concentrations of vinblastine.
This was not simply due to a toxic effect brought about by the rela-
tively high concentrations of vinblastine used, as this increase was
not observed in MDCKII-MRP1 or wild-type cells (Figure 4A and
data not shown). To investigate the ratio between GSH and
vinblastine transported by MDCKII-MRP2 cells, monolayers were
incubated in the presence of various concentrations of [3H]vinblas-
tine in either the apical or basal compartment and radioactivity
appearing in the opposite compartment was measured. In a parallel
sample, the concentration of GSH was measured. Table 3 shows
that an increase in vinblastine flux was accompanied with a
concomitant increase in GSH export. The ratio vinblastine/GSH
transported was between two and three at the concentrations
tested.
We have shown before that daunorubicin is not transported by
MDCKII-MRP2 cells (Evers et al, 1998), whereas it is transported
380 R Evers et al
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Figure 3 Transepithelial flux of sulfinpyrazone by MDCKII and MDCKII-
MRP2 monolayers. (A) At t = 0 sulfinpyrazone (0.2 mM) was applied to either
the apical or basal compartment, and the percentage of sulfinpyrazone
appearing in the opposite compartment was determined by HPLC analysis.
Transport is presented as the fraction of sulfinpyrazone added at the
beginning of the experiment appearing in the opposite compartment.
Samples were taken at t = 1 and 2 h. (B, C, D) Same as A, but with 0.8, 1.6,
or 3.2 mM sulfinpyrazone, respectively. Dashed line and l l: translocation from
the basal to the apical compartment. Continuous line and n n: translocation
from the apical to the basal compartment. Experiments were performed in
duplicateat low rate by MDCKII-MRP1 cells (Bakos et al, 1998). We
measured the GSH flux in the presence of various concentrations
of daunorubicin (2–50 mM). No significant effect was observed on
GSH transport under these conditions (data not shown).
DISCUSSION
In this paper we show that GSH export in MDCKII-MRP1 cells is
blocked by the inhibitors of organic anion transporters sulfinpyra-
zone, benzbromarone and probenecid, whereas export is partially
inhibited by indomethacin. These results are in agreement with
earlier findings that these compounds are inhibitors of drug trans-
port by MRP1 (Feller et al, 1995; Evers et al, 1996; Holló et al,
1996; Heijn et al, 1997). Benzbromarone also blocked GSH export
in the MDCKII-MRP2 cells, and probenecid gave a partial inhibi-
tion. Previously, we found that sulfinpyrazone and indomethacin
had a stimulatory rather than an inhibitory effect on the transport
of  S-(2,4-dinitrophenyl)-glutathione (DNP-GS) by MDCKII-
MRP2 cells (Evers et al, 1998). Here we show that low concentra-
tions of sulfinpyrazone and indomethacin also stimulate GSH
export in MDCKII-MRP2 cells, whereas high concentrations
inhibit. As GSH export by MDCKII-MRP2 cells increases in the
presence of vinblastine as well, our results suggest that transport
of these drugs is associated with export of GSH. Transport
experiments with a concentration range of sulfinpyrazone indicate
that the transport mechanism may be more complex than obliga-
tory co-transport of drug with GSH, as unmodified sulfinpyrazone
is also transported by MDCKII-MRP2 cells at concentrations
where GSH export is inhibited (Table 2). These data strongly
suggest that sulfinpyrazone is also transported without GSH.
A critical point in the interpretation of our transport data with
vinblastine is the assumption that this compound is not conjugated
to GSH or other negatively charged groups. The evidence avail-
able suggests that such conjugates do not exist for anthracyclines
or vinca alkaloids (Tew, 1994). Zaman et al (1995) analysed the
medium from MRP1-overexpressing cells incubated in the pres-
ence of vincristine or daunorubicin and found that all drug recov-
ered was in the unmodified form. The simplest interpretation of
our data is that vinblastine is transported as free drug.
Several lines of evidence indicate that GSH is required for the
transport of cytotoxic drugs by MRP1 (Versantvoort et al, 1995;
Zaman et al, 1995; Loe et al, 1996; 1998; Rappa et al, 1997).
However, in none of these experiments the stochiometry between
drug and GSH transport was determined. In the MDCKII-MRP2
cells we observed that the GSH flux was dependent on the vinblas-
tine concentration. The exact stochiometry between the amount
of vinblastine and GSH transported is difficult to calculate.
Vinblastine is a relatively hydrophobic compound that diffuses
MRP and drug/glutathione transport 381
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Figure 4 Flux of GSH from MDCKII-derived clones in the presence of vinblastine. At t = 0 the indicated concentrations of vinblastine were applied to both the
apical and basal compartment, and the amount of glutathione appearing in both compartments was determined. Experiments were performed in the presence of
PSC833 (0.1 mM) and acivicin (0.5 mM). Samples were taken at t = 30, 60, and 120 min. (A) MDCKII cells, (B) MDCKII-MRP2 cells. Experiments were
performed in duplicateeasily over the plasma membrane and the determination of net
flux therefore requires substantial correction factors. Nevertheless,
our experiments strongly suggest that both compounds are
co-transported (Table 3).
The stimulation of GSH export by sulfinpyrazone and vinblas-
tine makes it unlikely that GSH is required to allosterically regu-
late the transport of drugs by MRP2. We propose a working model
in which MRP2 has two drug-binding sites: one with a relatively
high affinity for GSH (G-site) and a low affinity for drug, and one
with a relatively high affinity for drug and a low affinity for GSH
(D-site). The presence of a GSH-binding site is not unlikely as
Taguchi et al (1997) have shown by vanadate trapping experi-
ments that GSH can bind to MRP1, and Bakos et al (2000) have
found GSH-induced ATP-ase activity in MRP1- and MRP2-
containing membrane vesicles. We think that both binding sites are
occupied by GSH in the absence of drugs, resulting in a slow
export of GSH (Paulusma et al, 1999). We cannot rule out the
alternative, however, that GSH export in the absence of added
drug is accompanied by a not as yet identified intracellular
metabolite that is binding to the D-site and is co-transported with
GSH. We propose that at low drug concentrations the G-site
remains occupied by GSH and the D-site becomes occupied by
drug, resulting in co-transport of both compounds. We speculate
that the two sites show positive cooperativity as we observe stimu-
lation of GSH transport in the presence of the organic anions
sulfinpyrazone and indomethacin. This may also explain why
sulfinpyrazone is able to stimulate DNP-GS export in MDCKII-
MRP2 cells (Evers et al, 1998). At high drug concentrations some
(negatively charged) drugs appear to be able to occupy both the
G- and D-site. In the case of sulfinpyrazone this results in transport
of drug alone by MRP2. That sulfinpyrazone is directly trans-
ported by MRP2 and not by another fortuitously activated canine
transporter is further substantiated by the finding that sulfinpyra-
zone inhibits the vinblastine flux by MDCKII-MRP2 cells (data
not shown). MRP1 and MRP2 do not require free GSH for the trans-
port of compounds that are conjugated to glutathione, glucuronide
or sulfate (Jedlitschky et al, 1996; 1997; Evers et al, 1998; Ito et al,
1998). We suggest that such substrates have a relatively high affinity
for both the G- and D-site and are therefore transported efficiently
without requiring GSH or stimulating GSH export.
For MRP1, Heijn et al (1997) found, in uptake experiments with
MRP1-containing vesicles, that DNP-GS uptake was non-
competitively inhibited by daunorubicin, whereas uptake of GSSG
was competitively inhibited. These authors proposed a substrate-
binding site on MRP1 that consists of a pocket in which both
daunorubicin and DNP-GS or GSSG bind in random order to
different, only partly overlapping, sites. In this pocket, binding of
a second compound is influenced by the compound that was bound
first. Detailed in vitro experiments with MRP1- and MRP2-
containing vesicles are required to critically test such models.
Whether MRP2 plays a role in clinical drug resistance remains
to be seen. However, the availability of efficient inhibitors for this
transporter would be helpful to address this question. The work
presented here indicates that known inhibitors of organic anion
transporters are either poor blockers of MRP2 or have the unex-
pected effect that they stimulate GSH export, something that may
induce secondary reactions in cells. Induction of GSH export by
sulfinpyrazone is not restricted to MDCKII-MRP2 cells, as we
also observe it in other cell lines stably expressing MRP2 (M Kool
and PB, manuscript in preparation), indicating that the observa-
tions described here are not cell-line-dependent.
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